Defect‐Rich Metastable MoS₂ Promotes Macrophage Reprogramming in Breast Cancer: A Clinical Perspective

Abstract

Tumor‐associated macrophages (TAMs) play a crucial function in solid tumor antigen clearance and immune suppression. Notably, 2D transitional metal dichalcogenides (i.e., molybdenum disulfide (MoS2) nanozymes) with enzyme‐like activity are demonstrated in animal models for cancer immunotherapy. However, in situ engineering of TAMs polarization through sufficient accumulation of free radical reactive oxygen species for immunotherapy in clinical samples remains a significant challenge. In this study, defect‐rich metastable MoS2 nanozymes, i.e., 1T2H‐MoS2, are designed via reduction and phase transformation in molten sodium as a guided treatment for human breast cancer. The as‐prepared 1T2H‐MoS2 exhibited enhanced peroxidase‐like activity (≈12‐fold enhancement) than that of commercial MoS2, which is attributed to the charge redistribution and electronic state induced by the abundance of S vacancies. The 1T2H‐MoS2 nanozyme can function as an extracellular hydroxyl radical generator, efficiently repolarizing TAMs into the M1‐like phenotype and directly killing cancer cells. Moreover, the clinical feasibility of 1T2H‐MoS2 is demonstrated via ex vivo therapeutic responses in human breast cancer samples. The apoptosis rate of cancer cells is 3.4 times greater than that of cells treated with chemotherapeutic drugs (i.e., doxorubicin).